P185 Life cycle assessment and cradle-to-grave carbon footprint of a multidose reservoir dry powder inhaler

Dry powder inhalers (DPIs) have about 20-fold lower carbon footprint (CO2FP) than metered dose inhalers (MDIs) with estimates of CO2FP between 1.5 and 6 kg CO2e for a 200-dose DPI. GSK’s Carbon Trust-verified analysis including Relvar and Seretide Accuhaler is about 1 kg CO2e/inhaler, and Product Carbon Footprint analysis of Spiriva Respimat 0.780 kg CO2e. Still, limited data is available on CO2FP and Life Cycle Assessment (LCA) of different types of DPIs.We conducted a Cradle-to-Grave (CTG) CO2FP analysis and LCA of four different Easyhaler® (EH) products available for the treatment of asthma and COPD (budesonide-formoterol; salmeterol-fluticasone; salbutamol, and formoterol EH). In-depth data collection from Orion in-house data, suppliers, and reference databases was conducted in 2019. Analyses were performed by ISO14001:2015 and 9001:2015 certified Carbon Footprint Ltd.The total CTG life cycle emissions for one EH (average) was 0.588 kg CO2e (range 0.514–0.664 kg). Emissions from manufacture accounted for 60% (range 54–65%). In comparison, emissions from distribution accounted for less than 2%, indicating that most potential for improvement lies in manufacture processes.Patients with asthma or COPD, and treating physicians alike, are increasingly aware of climate change and this affects even their treatment choices. When considering the climate impact of inhalation therapy, DPIs, like EH, have a minimal carbon footprint compared with MDI.Abstract P185 Figure 1